Dataset Information

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.

ABSTRACT:

Background

The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT).

Methods

Peripheral blood samples were collected for measuring monocytic (M-) MDSCs (CD14^posHLA-DR^low/neg) and early-stage (E-) MDSCs (Lin^negHLA-DR^negCD33^posCD11b^pos) before and after ASCT. Clinical outcomes following ASCT differed according to the frequency of each MDSC phenotype.

Results

In the pre-ASCT analyses, lower M-MDSCs (ConclusionsOur data demonstrate that pre-ASCT M-MDSCs are correlated with poor clinical outcomes after ASCT through reduced cytotoxicity of melphalan. We propose that targeting CSF1R on these cells may improve the results of ASCT in MM.

SUBMITTER: Lee SE

PROVIDER: S-EPMC6367772 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.

Lee Sung-Eun SE Lim Ji-Young JY Kim Tae Woo TW Ryu Da-Bin DB Park Sung Soo SS Jeon Young-Woo YW Yoon Jae-Ho JH Cho Byung-Sik BS Eom Ki-Seong KS Kim Yoo-Jin YJ Kim Hee-Je HJ Lee Seok S Cho Seok-Goo SG Kim Dong-Wook DW Lee Jong Wook JW Min Chang-Ki CK

Journal for immunotherapy of cancer 20190207 1

<h4>Background</h4>The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT).<h4>Methods</h4>Peripheral blood samples were collected for measuring monocytic (M-) MDSCs (CD14<sup>pos</sup>HLA-DR<sup>low/neg</sup>) and early-stage (E-) MDSCs (Lin<sup>neg</sup>HLA-DR<sup>neg</sup>CD33<sup>pos</sup>CD11b<sup>pos</sup>) before and after ASCT. Clinical outcomes following ...[more]

PMID: 30732646

Similar Datasets

Project description:BackgroundInduction therapy followed by high-dose chemotherapy and autologous transplantation is the standard treatment for suitable patients with multiple myeloma.ObjectiveThe aim of this study was to assess whether induction therapy with thalidomidecontaining regimens was associated with improved results compared to vincristine, doxorubicin, and dexamethasone, and whether cyclophosphamide, thalidomide, and dexamethasone were associated with better results than thalidomide and dexamethasone.MethodsThe records of 152 patients who underwent autologous transplantation at this institution from August of 2004 to January of 2012 were reviewed, selecting those with at least partial response to a maximum of eight cycles of induction therapy and sufficient follow-up information for analysis.ResultsThis study included 89 patients; 44 were female, with a mean age of 55 years (there was a significant trend for increasing age over the years of the study).The median number of induction therapy cycles was four, again with a trend of increase over the years.At least a very good partial response to induction therapy was achieved more often in the cyclophosphamide, thalidomide, and dexamethasone group (61.1%) and in the thalidomide and dexamethasone group (59.2%) than in the vincristine, doxorubicin, and dexamethasone group (16.2%). The overall median progression-free survival was 34 months, with no statistically significant difference between the three groups. The overall median survival was not reached, and there was no significant difference between the three groups; the estimated five-year overall survival was 55%.ConclusionAlthough the quality of responses appeared to be better with thalidomidecontaining regimens, these improvements did not translate into improved long-term outcomes. Given its track record, cyclophosphamide, thalidomide, and dexamethasone is currently considered the preferred regimen for first-line induction therapy in the Brazilian public health system.

Dataset Information

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.

Background

Methods

Results

Publications

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets